|1.||Giannarelli, Chiara: 1 article (01/2012)|
|2.||Zafar, M Urooj: 1 article (01/2012)|
|3.||Ibanez, Borja: 1 article (01/2012)|
|4.||Ruiz, Josè M Garcia: 1 article (01/2012)|
|5.||Badimon, Juan J: 1 article (01/2012)|
|6.||Fuster, Valentin: 1 article (01/2012)|
|7.||Feuerstein, Giora: 1 article (01/2012)|
|8.||Connolly, Thomas M: 1 article (01/2012)|
|9.||Alique, Matilde: 1 article (01/2012)|
|10.||Cimmino, Giovanni: 1 article (01/2012)|
12/01/2009 - "WAY-252623 (LXR-623) is a highly selective and orally bioavailable synthetic modulator of LXR, which demonstrated efficacy for reducing lesion progression in the murine LDLR(-/-) atherosclerosis model with no associated increase in hepatic lipogenesis either in this model or Syrian hamsters. "
06/01/2009 - "LXR-623 is a synthetic ligand for LXRs alpha and beta that has shown promise in animal models of atherosclerosis. "
01/01/2012 - "The aim of this study was to investigate the effects of liver X receptors (LXRs)-β preferential activation by LXR-623 (WAY-252623), a novel LXRs agonist, on plaque progression/regression in a rabbit model of advanced atherosclerosis. "
04/01/2010 - "While discontinued for CNS safety concerns, investigation of LXR-623 supports atherosclerosis as a clinical indication, and the possibility of identifying LXR agonists with profiles that avoid the strong lipogenic effects of full LXRalpha/beta agonists. "
04/01/2010 - "While atherosclerosis is not yet clinically validated, Wyeth's LXRalpha/beta agonist LXR-623 indicated the key LXR target genes involved in RCT (ABCA1 and ABCG1) are upregulated in peripheral blood cells in a dose-dependent manner. "